Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.

Annals of hematology - 16 Feb 2026

Ji Qingli, Jiang Xinwen, Li Xiaoqing, Cao Chen, Zhang Xinrui, Zhou Minran, Ma Sai, Chen Chunyan

Abstract excerpt

Although KIT mutations hold significant prognostic value in acute myeloid leukemia (AML), their impact on selecting first-line treatment remains unclear. This retrospective study of 222 newly diagnosed AML patients therefore compared the efficacy of venetoclax plus azacitidine (VA) versus intensive chemotherapy (IC) in KIT-mutated AML, while also exploring the prognostic implications of KIT mutation subtypes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Disease-Free Survival

Share to Leukemia, Myeloid, Acute

Share to Proto-Oncogene Proteins c-kit

Share to Sulfonamides

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 41697365
DOI: 10.1007/s00277-026-06841-4
PMCID: PMC12909349

Genes

KIT
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.PMID 41697365Read ↗

Superior Response and Survival of Intensive Chemotherapy Over Venetoclax Plus Azacitidine in Newly Diagnosed KIT-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.Semantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Semantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.